Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Pediatric Hematology
What is your criteria for considering oral, or IV, iron repletion in pediatric patients referred to Hematology for restless leg syndrome?
Related Questions
What is your approach to an infant (<12 mo) with new onset petechiae and thrombocytopenia, with labs consistent with ITP?
How do you counsel patients with acute intermittent porphyria when it comes to fasting for religious reasons?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
For von Willebrand type 2B, do you expect a decline in platelet count over time as vWF increases with age?
How do you approach the work-up for a patient with iron deficiency anemia who is not responding to oral iron therapy?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
In light of the Haven 7 trial results, what considerations should be made regarding the monitoring and management of potential long-term adverse effects of emicizumab in infants?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How should clinicians approach the decision to use apixaban, or other DOACs, in pediatric patients with acute lymphoblastic leukemia or lymphoma who have additional risk factors for VTE, such as obesity or a family history of thrombosis, given the negative outcome of the PREVAPIX-ALL trial?
